Clinical trials of novel alternative hemostatic agents for hemophilia
| Novel Agent . | NCT . | Sponsor . | Route . | Subject . | Status . |
|---|---|---|---|---|---|
| 1. Coagulation factor mutants or mimics | |||||
| ACE910 | NCT02622321 | Hoffmann-La Roche | SQ | HA/I | Phase 1/2 ongoing |
| NCT02847637 | Phase 3 planned | ||||
| Super FVa | NA | Bayer | IV | — | Preclinical ongoing |
| FXaI16→L | NCT01897142 | Pfizer | IV | HA/I | Phase 1 ongoing |
| FVIII-∆P/F | NA | Avelas | IV; AAV | — | Preclinical ongoing |
| 2. Natural anticoagulant knock-down or disruption | |||||
| ALN-AT | NCT02554773 | Alnylam | SQ | HA/HB/I | Phase 1, 2 ongoing |
| NCT03001830 | SQ | Phase 3 planned | |||
| Anti-TFPI | NCT02540187 | Bayer | IV, SQ | HA/HB/I | Phase 1 ongoing |
| NCT02571569 | Phase 2, 3 planned | ||||
| Anti-TFPI | NCT015555749 | Novo Nordisk | IV, SQ | HA/HB | Phase 1 ongoing |
| NCT02490787 | Phase 2, 3 planned | ||||
| Anti-TFPI | NCT02540187 | Pfizer | IV, SQ | HA/HB | Phase 1 ongoing |
| NCT02974855 | Phase 2, 3 planned | ||||
| KRK α1AT | — | ApcinteX | IV | — | Phase 1 planned |
| Novel Agent . | NCT . | Sponsor . | Route . | Subject . | Status . |
|---|---|---|---|---|---|
| 1. Coagulation factor mutants or mimics | |||||
| ACE910 | NCT02622321 | Hoffmann-La Roche | SQ | HA/I | Phase 1/2 ongoing |
| NCT02847637 | Phase 3 planned | ||||
| Super FVa | NA | Bayer | IV | — | Preclinical ongoing |
| FXaI16→L | NCT01897142 | Pfizer | IV | HA/I | Phase 1 ongoing |
| FVIII-∆P/F | NA | Avelas | IV; AAV | — | Preclinical ongoing |
| 2. Natural anticoagulant knock-down or disruption | |||||
| ALN-AT | NCT02554773 | Alnylam | SQ | HA/HB/I | Phase 1, 2 ongoing |
| NCT03001830 | SQ | Phase 3 planned | |||
| Anti-TFPI | NCT02540187 | Bayer | IV, SQ | HA/HB/I | Phase 1 ongoing |
| NCT02571569 | Phase 2, 3 planned | ||||
| Anti-TFPI | NCT015555749 | Novo Nordisk | IV, SQ | HA/HB | Phase 1 ongoing |
| NCT02490787 | Phase 2, 3 planned | ||||
| Anti-TFPI | NCT02540187 | Pfizer | IV, SQ | HA/HB | Phase 1 ongoing |
| NCT02974855 | Phase 2, 3 planned | ||||
| KRK α1AT | — | ApcinteX | IV | — | Phase 1 planned |
NCT indicates clinicaltrials.gov number.
AAV, adeno-associated virus; HA, hemophilia A; HB, hemophilia B; I, inhibitor; NA, not available; SQ, subcutaneous.